Bristol-Myers Squibb Company continues to evolve its business to a leading diversified specialty biopharma company, focusing on discovering, developing, and delivering innovative medicines that address serious unmet medical needs. The company is committed to optimizing global brands and key markets, which accelerates growth of several key products. The organization is also evolving its commercial model and growing its marketed product portfolio in alignment with its overall strategy. Significant investments are being made in biologics manufacturing capabilities, which is essential for supporting its deep pipeline of innovative medicines. The company's research and development programs are managed on a portfolio basis from early discovery through late-stage development, ensuring an appropriate balance of early-stage and late-stage programs to support future growth. The company continually evaluates its portfolio to align with business needs and market dynamics. Additionally, the firm emphasizes the importance of mobilizing and deploying IT-based resources in combination with leveraging the value of other resources and capabilities. IT capabilities are critical in transforming the firm into a competitive force, as they represent the application of technology, knowledge, practices, and management skills to further organizational goals. The company recognizes the need for effective information management capability, which includes providing data and information to users with appropriate levels of accuracy, timeliness, reliability, security, confidentiality, connectivity, and access. This capability is essential for responding to changing business needs and directions. The firm is also focused on maintaining operational efficiency and enhancing its organizational capabilities through strategic resource allocation and investment decisions. The integration of technology into business processes is vital for achieving operational flexibility and improving firm performance. The companyâ€™s strategic management practices are designed to support business innovation and transformation, ensuring that its operations are aligned with market-based performance metrics. Furthermore, the firm is committed to continuous improvement and disciplined capital allocation, which are necessary for sustaining competitive advantage in a dynamic market environment. The management's actions are directed towards leveraging strategic resources and enhancing capabilities to drive performance gains and value creation across its operations. The company also recognizes the importance of external influences and market responsiveness in shaping its strategic decisions and operational strategies. Overall, Bristol-Myers Squibb's focus on IT capability, resource mobilization, and strategic alignment underscores its commitment to achieving long-term business success and resilience in the biopharmaceutical industry.